LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000249.4:c.1964T>C
MLH1
· NP_000240.1:p.(Ile655Thr)
· NM_000249.4
GRCh37: chr3:37090075 T>C
·
GRCh38: chr3:37048584 T>C
Gene:
MLH1
Transcript:
NM_000249.4
Final call
Likely Benign
BS3 supporting
BP4 supporting
Variant details
Gene
MLH1
Transcript
NM_000249.4
Protein
NP_000240.1:p.(Ile655Thr)
gnomAD AF
5.5158497011525024e-05 (v4.1)
ClinVar
Likely benign
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
BS3 Supporting: exact-variant assays showed retained repair activity, MLH1 expression, and no detectable splicing abnormality.
2
BP4 Supporting: the exact HCI pathogenicity prior is 0.0077, below the VCEP threshold of 0.11.
Final determination:
Under Rule19 of the MLH1 VCEP Version 2.0 framework, at least two Supporting benign criteria are sufficient for a Likely Benign classification; BS3 Supporting and BP4 Supporting meet this rule.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.1964T>C is an exon-17 missense SNV, while the governing PVS1 decision-tree path applies to nonsense or frameshift variants predicted to undergo NMD. |
cspec
vcep_pvs1_decisiontree_mmr
pvs1_variant_assessment
PMID:17510385
PMID:31332305
|
| PS1 | Not met | Not met: the VCEP-listed same-residue comparator p.Ile655Phe is Uncertain significance, not the Pathogenic classification required for PS1. |
cspec
vcep_vcep_pilot_variants_mmr
|
| PS2 | Not assessed | Not assessed: affected probands were reported, but no parental testing or evidence establishing de novo origin was provided for PS2 point assignment. |
cspec
PMID:8938136
PMID:10970186
|
| PS3 | Not met | Not met: I655T retained 73.8% in-vitro mismatch-repair activity and >75% relative MLH1 expression, rather than demonstrating deficient function. |
cspec
vcep_functional_assay_svi_documentation_mmr
vcep_functional_assay_flowchart
PMID:17510385
|
| PS4 | N/A | Not applicable: the MLH1 VCEP explicitly marks PS4 Not Applicable. |
cspec
|
| PM1 | N/A | Not applicable: the MLH1 VCEP explicitly marks PM1 Not Applicable, regardless of residue 655 appearing within a listed interaction-domain interval. |
cspec
vcep_mmr_functional_domains
|
| PM2 | Not met | Not met: gnomAD v4.1 total AF is 5.51585e-05, above the VCEP PM2 threshold of 0.00002 (less than 1 in 50,000 alleles). |
cspec
gnomad_v4
vcep_vcep_pilot_variants_mmr
|
| PM3 | Not assessed | Not assessed: no documented CMMRD phenotype or phased pathogenic MLH1 variant in trans, and gnomAD v4.1 grpmax FAF 5.3e-05 exceeds the PM2_Supporting threshold of <0.00002. |
cspec
gnomad_v4
PMID:8938136
PMID:10970186
|
| PM4 | N/A | Not applicable: the MLH1 VCEP explicitly designates PM4 as Not Applicable, and c.1964T>C is a missense SNV without a protein-length change. |
cspec
PMID:17510385
PMID:31332305
|
| PM5 | Not met | Not met: the only VCEP-listed alternate residue-655 missense, p.Ile655Phe, is Uncertain significance rather than Pathogenic. |
cspec
vcep_vcep_pilot_variants_mmr
|
| PM6 | N/A | Not applicable: the VCEP marks PM6 as not applicable and directs assumed de novo evidence to its PS2 point system. |
cspec
|
| PP1 | Not assessed | Not assessed: no informative affected-relative genotypes or combined Bayes Likelihood Ratio were reported; the only family entry was explicitly non-informative. |
cspec
PMID:8938136
PMID:17510385
|
| PP2 | N/A | Not applicable: the MLH1 VCEP explicitly marks PP2 Not Applicable for this framework. |
cspec
|
| PP3 | Not met | Not met: HCI prior probability is 0.0077, below the PP3 Supporting threshold of >0.68 for missense variants. |
cspec
vcep_hci_priors_mlh1
|
| PP4 | Not assessed | Not assessed: two MSI-H colorectal tumors are reported, but MLH1 promoter methylation exclusion required by the VCEP is undocumented. |
cspec
PMID:10970186
PMID:11376800
|
| PP5 | N/A | Not applicable: the MLH1 VCEP explicitly marks PP5 Not Applicable. |
cspec
|
| BA1 | Not met | Not met: gnomAD v4.1 Grpmax FAF is 0.000053 (0.0053%), below the VCEP BA1 threshold of 0.001 (0.1%). |
cspec
gnomad_v4
vcep_vcep_pilot_variants_mmr
|
| BS1 | Not met | Not met: gnomAD v4.1 Grpmax FAF is 0.000053 (0.0053%), below the VCEP BS1 lower threshold of 0.0001 (0.01%). |
cspec
gnomad_v4
vcep_vcep_pilot_variants_mmr
|
| BS2 | Not assessed | Not assessed: no documented in-trans pathogenic MLH1 variant, confirmed phase, qualifying late-onset cancer, or CMMRD assessment is available for the BS2 rule. |
cspec
vcep_vcep_pilot_variants_mmr
|
| BS3 | Met | Met at Supporting: I655T showed 73.8% repair activity, >75% MLH1 expression, and no detectable transcript-splicing abnormality in exact-variant assays. |
cspec
vcep_functional_assay_svi_documentation_mmr
vcep_functional_assay_flowchart
PMID:17510385
PMID:31332305
|
| BS4 | Not assessed | Not assessed: no non-segregating affected relatives or combined Bayes Likelihood Ratio below the VCEP thresholds were reported. |
cspec
|
| BP1 | N/A | Not applicable: the MLH1 VCEP explicitly marks BP1 Not Applicable for this framework. |
cspec
|
| BP2 | N/A | Not applicable: the MLH1 VCEP marks BP2 not applicable and directs evaluators to use BS2 instead. |
cspec
|
| BP3 | N/A | Not applicable: the MLH1 VCEP explicitly designates BP3 as Not Applicable, and c.1964T>C is a missense SNV rather than an in-frame deletion in a repeat region. |
cspec
PMID:17510385
PMID:31332305
|
| BP4 | Met | Met, Supporting: HCI prior probability is 0.0077, below the VCEP BP4 threshold of <0.11. |
cspec
vcep_hci_priors_mlh1
|
| BP5 | Not assessed | Not assessed: reported tumors are MSI-H, whereas BP5 requires qualifying MSS/no-loss tumors or BRAF V600E/MLH1 methylation evidence. |
cspec
PMID:10970186
PMID:11376800
|
| BP6 | N/A | Not applicable: the MLH1 VCEP explicitly marks BP6 Not Applicable. |
cspec
|
| BP7 | N/A | Not applicable: c.1964T>C is a coding missense variant, not a synonymous or intronic variant within BP7 scope. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.